CenterBook Partners LP Buys 1,988,751 Shares of The Oncology Institute, Inc. $TOI

CenterBook Partners LP lifted its position in The Oncology Institute, Inc. (NASDAQ:TOI) by 277.8% during the 3rd quarter, Holdings Channel reports. The firm owned 2,704,650 shares of the company’s stock after acquiring an additional 1,988,751 shares during the period. CenterBook Partners LP’s holdings in Oncology Institute were worth $9,439,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in Oncology Institute by 6.2% during the 3rd quarter. Vanguard Group Inc. now owns 4,545,245 shares of the company’s stock valued at $15,863,000 after buying an additional 264,358 shares during the last quarter. Tiff Advisory Services LLC increased its position in shares of Oncology Institute by 22.0% in the second quarter. Tiff Advisory Services LLC now owns 3,634,465 shares of the company’s stock valued at $7,451,000 after acquiring an additional 655,324 shares during the period. Balyasny Asset Management L.P. raised its stake in shares of Oncology Institute by 17.3% during the second quarter. Balyasny Asset Management L.P. now owns 2,518,337 shares of the company’s stock valued at $5,163,000 after acquiring an additional 371,005 shares during the last quarter. Marshall Wace LLP purchased a new stake in shares of Oncology Institute during the second quarter worth about $3,028,000. Finally, Geode Capital Management LLC boosted its holdings in shares of Oncology Institute by 231.7% during the second quarter. Geode Capital Management LLC now owns 1,279,443 shares of the company’s stock worth $2,623,000 after purchasing an additional 893,696 shares during the period. 36.86% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Oncology Institute news, Director Brad Hively sold 13,333 shares of the firm’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $3.77, for a total transaction of $50,265.41. Following the completion of the transaction, the director owned 683,721 shares of the company’s stock, valued at approximately $2,577,628.17. This trade represents a 1.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 8.50% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

TOI has been the topic of a number of research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Oncology Institute in a report on Wednesday, January 21st. BTIG Research reiterated a “buy” rating and issued a $7.00 price objective on shares of Oncology Institute in a research report on Tuesday, October 21st. Finally, Needham & Company LLC initiated coverage on Oncology Institute in a research note on Tuesday, November 25th. They set a “buy” rating and a $5.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $6.50.

Oncology Institute Stock Performance

TOI stock opened at $2.66 on Wednesday. The Oncology Institute, Inc. has a fifty-two week low of $0.60 and a fifty-two week high of $4.88. The company has a market capitalization of $261.69 million, a price-to-earnings ratio of -4.16 and a beta of 0.14. The business’s 50 day moving average price is $3.31 and its two-hundred day moving average price is $3.53.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.